Gene · 10
Papers3,552
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,552
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Analysis of NAT2 coding variants, combined genotypes, and haplotypes in prostate cancer susceptibility: a case-control study in an Iraqi Arab population. | Mol Biol Rep | 2026 | 42801388 | PubTator, text mining | PubMed |
| Genetic Variants at the NAT2 and HLA-DOA are Associated With Anti-Tuberculosis Drug-Induced Liver Injury Susceptibility and Clinical Manifestations in Western Chinese Populations. | Immun Inflamm Dis | 2026 | 42742466 | PubTator, text mining | PubMed |
| Regimen-Specific Population Pharmacokinetics of Isoniazid with and Without Rifamycin: A Bayesian Modeling Analysis of 6H, 3HR, and 3H2P2 Regimens. | Pharmaceutics | 2026 | 42654054 | PubTator, text mining | PubMed |
| Characterization of NAT2 Using Long-Read Sequencing: Allele, Diplotype, and Phenotype Call Accuracy Compared to Other Testing Strategies. | Clin Pharmacol Ther | 2026 | 42572153 | PubTator, text mining | PubMed |
| Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel. | Clin Pharmacol Ther | 2026 | 42538601 | PubTator, text mining | PubMed |
| Impact of NAT2 acetylation phenotype on toxicity in tuberculosis therapy: a systematic review and meta-analysis. | Pharmacogenomics | 2026 | 42531284 | PubTator, text mining | PubMed |
| Genetic Landscape of NAT2 in the Moroccan Population: Implications for Isoniazid Pharmacogenetics in Tuberculosis. | Clin Transl Sci | 2026 | 42504089 | PubTator, text mining | PubMed |
| Association of Selected Genetic Variants in CYP1A1, CYP2D6, NAT1 and NAT2 with Endometrial Cancer Risk: A Preliminary Case-Control Study. | Int J Mol Sci | 2026 | 42450020 | PubTator, text mining | PubMed |
| Correction to "Study on Genotyping Polymorphism and Sequencing of N-Acetyltransferase 2 (NAT2) Among Al-Ahsa Population". | Biomed Res Int | 2026 | 42444030 | PubTator, text mining | PubMed |
| Toxicity assessment of three emerging bisphenols (BPA, BPAP and BPC) and their binary mixtures in an advanced in vitro 3D HepG2 cell model. | Chem Biol Interact | 2026 | 42385970 | PubTator, text mining | PubMed |
| Systematic review on genetic polymorphisms associated with idiosyncratic drug-induced liver injury (iDILI): iDILInet as an interactive visualization tool. | Acta Pharm Sin B | 2026 | 42368566 | PubTator, text mining | PubMed |
| Global population frequencies of NAT2 star alleles observed in three large biobanks. | medRxiv | 2026 | 42326816 | PubTator, text mining | PubMed |
| Carcinogenic role of ESCO2 in cholangiocarcinoma: integration of bioinformatics analysis and experimental validation. | Transl Cancer Res | 2026 | 42305461 | PubTator, text mining | PubMed |
| Influence of NAT2 genetic variability on glycemic control in type 2 diabetes. | Clin Chim Acta | 2026 | 42229710 | PubTator, text mining | PubMed |
| NAT2 rs1495741 and anti-tuberculosis drug-induced liver injury in children: genetic association and risk prediction. | Front Pharmacol | 2026 | 42181880 | PubTator, text mining | PubMed |
| Sulfamethoxazole-trimethoprim-induced Stevens-Johnson syndrome in a NAT2 slow acetylator: A case for pre-emptive pharmacogenomic screening? | J Am Pharm Assoc (2003) | 2026 | 42142707 | PubTator, text mining | PubMed |
| Population-Specific Pharmacogenomic Profiling of NAT2, CYP2E1, and SLCO1B1 in Tuberculosis Patients from Southern Peru: A Feasibility Pilot Study. | J Pers Med | 2026 | 42042551 | PubTator, text mining | PubMed |
| Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in Thailand. | Front Public Health | 2026 | 41971281 | PubTator, text mining | PubMed |
| Construction of a survival model for predicting biochemical recurrence of prostate cancer based on propionate metabolism-related genes. | Transl Androl Urol | 2026 | 41971138 | PubTator, text mining | PubMed |
| Common Adverse Reactions and Management Strategies of First-Line Anti-Tuberculosis Drugs. | Infect Drug Resist | 2026 | 41939271 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10/papers